Home LiteratureArticle Details
PMID: 18982067 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

HIV-1 disease-influencing effects associated with ZNRD1, HCP5 and HLA-C alleles are attributable mainly to either HLA-A10 or HLA-B*57 alleles.

PloS one ·Vol. 3 ·No. 11 ·2008-00-00 ·Pages e3636

Catano G, Kulkarni H, He W, Marconi VC, Agan BK, Landrum M, Anderson S, Delmar J, Telles V, Song L, Castiblanco J, Clark RA, Dolan MJ, Ahuja SK

Abstract

A recent genome-wide association study (GWAS) suggested that polymorphisms in or around the genes HCP5, HLA-C and ZNRD1 confer restriction against HIV-1 viral replication or disease progression. Here, we also find that these alleles are associated with different aspects of HIV disease, albeit mainly in European Americans. Additionally, we offer that because the GWAS cohort was a subset of HIV-positive individuals, selected based in part on having a low viral load, the observed associations for viral load are magnified compared with those we detect in a large well-characterized prospective natural history cohort of HIV-1-infected persons. We also find that because of linkage disequilibrium (LD) patterns, the dominant viral load- and disease-influencing associations for the ZNRD1 or HLA-C and HCP5 alleles are apparent mainly when these alleles are present in HLA-A10- or HLA-B*57-containing haplotypes, respectively. ZNRD1 alleles lacking HLA-A10 did not confer disease protection whereas ZNRD1-A10 haplotypes did. When examined in isolation, the HCP5-G allele associates with a slow disease course and lower viral loads. However, in multivariate models, after partitioning out the protective effects of B*57, the HCP5-G allele associates with disease-acceleration and enhanced viral replication; these associations for HCP5-G are otherwise obscured because of the very strong LD between this allele and a subset of protective B*57 alleles. Furthermore, HCP5 and HLA-C alleles stratify B*57-containing genotypes into those that associate with either striking disease retardation or progressive disease, providing one explanation for the long-standing conundrum of why some HLA-B*57-carrying individuals are long-term non-progressors, whereas others exhibit progressive disease. Collectively, these data generally underscore the strong dependence of genotype-phenotype relationships upon cohort design, phenotype selection, LD patterns and populations studied. They specifically demonstrate that the influence of ZNRD1 alleles on disease progression rates are attributable to HLA-A10, help clarify the relationship between the HCP5, HLA-C and HLA-B*57 alleles, and reaffirm a critical role of HLA-B*57 alleles in HIV disease. Furthermore, as the protective B*57-containing genotypes convey striking salutary effects independent of their strong impact on viral control, it is conceivable that T cell-based therapeutic vaccine strategies aimed at reducing viral loads may be inadequate for limiting AIDS progression, raising the potential need for complementary strategies that target viral load-independent determinants of pathogenesis.

MeSH Terms
African Americans Alleles DNA-Binding Proteins/genetics Disease Progression Genotype HIV Infections/genetics,physiopathology HIV Long-Term Survivors HIV-1/genetics,immunology HLA-A Antigens/genetics HLA-B Antigens/genetics HLA-C Antigens/genetics Humans Kaplan-Meier Estimate Linkage Disequilibrium Major Histocompatibility Complex/genetics Phenotype Polymorphism, Genetic RNA, Long Noncoding RNA, Untranslated Viral Load Whites/genetics
Chemicals
DNA-Binding Proteins HCP5 long noncoding RNA, human HLA-A Antigens HLA-A10 antigen HLA-B Antigens HLA-B57 antigen HLA-C Antigens POLR1H protein, human RNA, Long Noncoding RNA, Untranslated
Authors & Affiliations
14 authors, click to expand affiliations / ORCID
Catano Gabriel
Veterans Administration Research Center for AIDS and HIV-1 Infection, South Texas Veterans Health Care System, San Antonio, TX, USA.
Kulkarni Hemant
He Weijing
Marconi Vincent C
Agan Brian K
Landrum Michael
Anderson Stephanie
Delmar Judith
Telles Vanessa
Song Li
Castiblanco John
Clark Robert A
Dolan Matthew J
Ahuja Sunil K
References (58)
58 references, click to expand
  1. Fine-specificity of cytotoxic T lymphocytes which recognize conserved epitopes of the Gag protein of human immunodeficiency virus type 1.
    J Gen Virol. 1996 Aug;77 ( Pt 8):1659-65 PMID: 8760412
  2. CCL3L1 and CCR5 influence cell-mediated immunity and affect HIV-AIDS pathogenesis via viral entry-independent mechanisms.
    Nat Immunol. 2007 Dec;8(12):1324-36 PMID: 17952079
  3. Duffy antigen receptor for chemokines mediates trans-infection of HIV-1 from red blood cells to target cells and affects HIV-AIDS susceptibility.
    Cell Host Microbe. 2008 Jul 17;4(1):52-62 PMID: 18621010
  4. The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?
    J Exp Med. 2008 Jan 21;205(1):7-12 PMID: 18195078
  5. Conserved extended haplotypes of the major histocompatibility complex: further characterization.
    Genes Immun. 2006 Sep;7(6):450-67 PMID: 16791278
  6. HLA and AIDS: a cautionary tale.
    Trends Mol Med. 2001 Sep;7(9):379-81 PMID: 11530315
  7. Concordance between the CC chemokine receptor 5 genetic determinants that alter risks of transmission and disease progression in children exposed perinatally to human immunodeficiency virus.
    J Infect Dis. 2001 Jun 1;183(11):1574-85 PMID: 11335892
  8. Identification of a novel human leukocyte antigen A26-restricted epitope in a conserved region of Gag.
    AIDS. 1996 Oct;10(12):1441-3 PMID: 8902082
  9. Modeling the impact of a partially effective HIV vaccine on HIV infection and death among women and infants in South Africa.
    J Acquir Immune Defic Syndr. 2006 Oct 1;43(2):219-25 PMID: 16951648
  10. The role of protective HCP5 and HLA-C associated polymorphisms in the control of HIV-1 replication in a subset of elite suppressors.
    AIDS. 2008 Feb 19;22(4):541-4 PMID: 18301071
  11. The influence of HLA genotype on AIDS.
    Annu Rev Med. 2003;54:535-51 PMID: 12525683
  12. Human leukocyte antigen class I genotypes in relation to heterosexual HIV type 1 transmission within discordant couples.
    J Immunol. 2008 Aug 15;181(4):2626-35 PMID: 18684953
  13. Viral replication capacity as a correlate of HLA B57/B5801-associated nonprogressive HIV-1 infection.
    J Immunol. 2007 Sep 1;179(5):3133-43 PMID: 17709528
  14. CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1-infected individuals.
    Nat Med. 2008 Apr;14(4):413-20 PMID: 18376407
  15. Understanding the benign nature of SIV infection in natural hosts.
    J Clin Invest. 2007 Nov;117(11):3148-54 PMID: 17975656
  16. Toward an AIDS vaccine.
    Science. 2008 May 9;320(5877):760-4 PMID: 18467582
  17. Patterns of ethnic diversity among the genes that influence AIDS.
    Hum Mol Genet. 2004 Apr 1;13 Spec No 1:R9-19 PMID: 14764621
  18. HIV-1 infection and AIDS dementia are influenced by a mutant MCP-1 allele linked to increased monocyte infiltration of tissues and MCP-1 levels.
    Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13795-800 PMID: 12374865
  19. The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility.
    Science. 2005 Mar 4;307(5714):1434-40 PMID: 15637236
  20. AIDS research. Promising AIDS vaccine's failure leaves field reeling.
    Science. 2007 Oct 5;318(5847):28-9 PMID: 17916696
  21. Transmission of human immunodeficiency virus type 1 from a patient who developed AIDS to an elite suppressor.
    J Virol. 2008 Aug;82(15):7395-410 PMID: 18495769
  22. Forecasting the future of HIV epidemics: the impact of antiretroviral therapies & imperfect vaccines.
    AIDS Rev. 2003 Apr-Jun;5(2):113-25 PMID: 12876900
  23. Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection.
    JAMA. 2006 Sep 27;296(12):1498-506 PMID: 17003398
  24. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma.
    Science. 1996 May 24;272(5265):1167-70 PMID: 8638160
  25. The differential ability of HLA B*5701+ long-term nonprogressors and progressors to restrict human immunodeficiency virus replication is not caused by loss of recognition of autologous viral gag sequences.
    J Virol. 2003 Jun;77(12):6889-98 PMID: 12768008
  26. Host genetic determinants of HIV pathogenesis: an immunologic perspective.
    Curr Opin HIV AIDS. 2008 May;3(3):342-8 PMID: 19372988
  27. Estimating the benefit of an HIV-1 vaccine that reduces viral load set point.
    J Infect Dis. 2007 Feb 15;195(4):546-50 PMID: 17230414
  28. Impact of MHC class I diversity on immune control of immunodeficiency virus replication.
    Nat Rev Immunol. 2008 Aug;8(8):619-30 PMID: 18617886
  29. Identification of a novel HLA-A25-restricted epitope in a conserved region of p24 gag (positions 71-80).
    AIDS. 1996 Mar;10(3):348-50 PMID: 8882684
  30. Maintenance of viral suppression in HIV-1-infected HLA-B*57+ elite suppressors despite CTL escape mutations.
    J Exp Med. 2006 May 15;203(5):1357-69 PMID: 16682496
  31. An HIV vaccine--evolving concepts.
    N Engl J Med. 2007 May 17;356(20):2073-81 PMID: 17507706
  32. Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy.
    Immunity. 2007 Sep;27(3):406-16 PMID: 17892849
  33. AIDS/HIV. A STEP into darkness or light?
    Science. 2008 May 9;320(5877):753-5 PMID: 18467578
  34. Explaining, predicting, and treating HIV-associated CD4 cell loss: after 25 years still a puzzle.
    JAMA. 2006 Sep 27;296(12):1523-5 PMID: 17003402
  35. HIV-1 diversity versus HLA class I polymorphism.
    Trends Immunol. 2005 Jan;26(1):41-7 PMID: 15629408
  36. Sensitivity analysis for the assessment of causal vaccine effects on viral load in HIV vaccine trials.
    Biometrics. 2003 Sep;59(3):531-41 PMID: 14601754
  37. A high-resolution HLA and SNP haplotype map for disease association studies in the extended human MHC.
    Nat Genet. 2006 Oct;38(10):1166-72 PMID: 16998491
  38. Host factors associated with outcome from primary human immunodeficiency virus-1 infection.
    Curr Opin HIV AIDS. 2008 Jan;3(1):28-35 PMID: 19372941
  39. Apolipoprotein (apo) E4 enhances HIV-1 cell entry in vitro, and the APOE epsilon4/epsilon4 genotype accelerates HIV disease progression.
    Proc Natl Acad Sci U S A. 2008 Jun 24;105(25):8718-23 PMID: 18562290
  40. Independent effects of genetic variations in mannose-binding lectin influence the course of HIV disease: the advantage of heterozygosity for coding mutations.
    J Infect Dis. 2008 Jul 1;198(1):72-80 PMID: 18498240
  41. Identification of host proteins required for HIV infection through a functional genomic screen.
    Science. 2008 Feb 15;319(5865):921-6 PMID: 18187620
  42. Analytic insights into the population level impact of imperfect prophylactic HIV vaccines.
    J Acquir Immune Defic Syndr. 2007 Aug 1;45(4):454-67 PMID: 17554215
  43. Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection.
    AIDS. 2003 Dec 5;17(18):2581-91 PMID: 14685052
  44. What constitutes efficacy for a human immunodeficiency virus vaccine that ameliorates viremia: issues involving surrogate end points in phase 3 trials.
    J Infect Dis. 2003 Jul 15;188(2):179-93 PMID: 12854072
  45. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection.
    Ann Intern Med. 1997 Jun 15;126(12):946-54 PMID: 9182471
  46. AIDS restriction HLA allotypes target distinct intervals of HIV-1 pathogenesis.
    Nat Med. 2005 Dec;11(12):1290-2 PMID: 16288280
  47. A whole-genome association study of major determinants for host control of HIV-1.
    Science. 2007 Aug 17;317(5840):944-7 PMID: 17641165
  48. HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors.
    Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2709-14 PMID: 10694578
  49. Race-specific HIV-1 disease-modifying effects associated with CCR5 haplotypes.
    Proc Natl Acad Sci U S A. 1999 Oct 12;96(21):12004-9 PMID: 10518566
  50. Potential public health impact of imperfect HIV type 1 vaccines.
    J Infect Dis. 2005 Feb 1;191 Suppl 1:S85-96 PMID: 15627235
  51. Influence of host genetic variation on susceptibility to HIV type 1 infection.
    J Infect Dis. 2005 Feb 1;191 Suppl 1:S68-77 PMID: 15630678
  52. Global survey of genetic variation in CCR5, RANTES, and MIP-1alpha: impact on the epidemiology of the HIV-1 pandemic.
    Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5199-204 PMID: 11320252
  53. Prospects for an AIDS vaccine.
    Nat Med. 2004 Mar;10(3):221-3 PMID: 14991035
  54. A high-resolution linkage-disequilibrium map of the human major histocompatibility complex and first generation of tag single-nucleotide polymorphisms.
    Am J Hum Genet. 2005 Apr;76(4):634-46 PMID: 15747258
  55. Killer immunoglobulin-like receptors and HLA act both independently and synergistically to modify HIV disease progression.
    Genes Immun. 2005 Dec;6(8):683-90 PMID: 16121209
  56. A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci.
    PLoS Genet. 2008 Mar;4(3):e1000041 PMID: 18369459
  57. Genetic influences on HIV infection: implications for vaccine development.
    Sex Health. 2005;2(2):53-62 PMID: 16335742
  58. Definition of two new epitopes on human immunodeficiency virus type 1 gag protein recognized by human CD8+ cytotoxic T lymphocyte clones.
    J Clin Virol. 2003 May;27(1):38-43 PMID: 12727527
Article Info
Journal
PloS one
Abbr.
PLoS One
ISSN
1932-6203
Published
2008-00-00
Epub
2008-00-04
Pages
e3636
Language
English
Region
United States
NLM ID
101285081
PMCID
PMC2574440
Subset
IM
Grants
NIAID NIH HHS · HU0001-05-2-0011 · United States
NIAID NIH HHS · R37 AI046326 · United States
NIMH NIH HHS · MH069270 · United States
NIMH NIH HHS · R01 MH069270 · United States
NIAID NIH HHS · R01 AI043279 · United States
NIAID NIH HHS · AI043279 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com